Healthcare Industry News: Acute Coronary Syndrome
News Release - February 11, 2010
Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical AffairsBolsters Company's Expertise in Areas of Oncology and Hematology
PARSIPPANY, N.J., Feb. 11 (Healthcare Sales & Marketing Network) -- Daiichi Sankyo, Inc. (DSI) announced today that Jay M. Feingold, M.D., Ph.D., has been appointed Vice President of Medical Affairs. Dr. Feingold will manage strategic direction of the company's Medical Affairs department and oversee more than 90 scientists, researchers and field-based medical teams responsible for collaborating with the company's clinical research arm, commercial organization and partners. Medical Affairs is responsible for providing physicians, key opinion leaders, regulatory agencies and professional organizations with medical and scientific information in the areas of clinical studies, outcomes research and disease management programs, among others. Dr. Feingold's vast experience in oncology and hematology will continue to drive the company's current cardiovascular portfolio and shape its pipeline.
"I am very excited to join Daiichi Sankyo and look forward to working with my colleagues to continue to build relationships with health care providers to improve medical care and enhance professional education," said Dr. Feingold. "As we develop new and innovative therapies it will be important to ensure that critical safety and efficacy information is understood by practitioners, regulatory agencies, payors and patients. Medical Affairs plays a key role in communicating this information."
Dr. Feingold also becomes a member of DSI's Executive Committee, which is responsible for guiding the organization's short- and long-term strategic and financial objectives.
DSI is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd. The U.S. headquarters facility in Parsippany, New Jersey houses 480 employees, including corporate offices and all functions that support the company's commercial operations. In addition, the company has a clinical development division in Edison, New Jersey that employs 350 people who oversee clinical trials being conducted around the world.
Prior to joining DSI, Dr. Feingold worked with Wyeth Pharmaceuticals, where he most recently led Oncology Global Clinical Development. Prior to that, he was multi-therapeutic area head in Global Medical Affairs with responsibility for the hematology, oncology and central nervous system (CNS) franchises.
Dr. Feingold, a member of the American Society of Hematology and American Society of Clinical Oncology, is a molecular biologist who earned his Bachelor of Science degree from S.U.N.Y. Stony Brook and his Medical Degree, Master of Science and Ph.D. degrees from Albert Einstein College of Medicine. Dr. Feingold did his residency in Pediatrics and fellowship in Pediatric Hematology/Oncology at the UCLA Center for the Health Sciences.
About Daiichi Sankyo, Inc.
Daiichi Sankyo Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd., which is a global pharmaceutical innovator. The headquarters company was established in 2005 from the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research
and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes and Acute Coronary Syndrome. Also important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit www.dsi.com.
Source: Daiichi Sankyo
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.